Table 2 Detailed breakdown of immunotherapy, and SUV measurements of the left and right ventricle and tumour
Patient | Immunotherapy | Chemotherapy | Baseline LVmax:BP | Baseline RVmax:BP | Heterogeneity index (LVmax/LVmean) | Heterogeneity index (RVmax/RVmean) | LV: tumour uptake LVmax:Tumourmax | RV: tumour uptake RVmax:Tumourmax |
|---|---|---|---|---|---|---|---|---|
1 | Pembrolizumab | Carboplatin and pemetrexed | 2.55 | 1.64 | 1.54 | 1.53 | 0.86 | 0.55 |
2 | Pembrolizumab | – | 2.05 | 1.56 | 1.44 | 1.59 | 0.58 | 0.44 |
3 | Pembrolizumab | – | 2.46 | 1.68 | 1.92 | 1.81 | 1.07 | 0.73 |
4 | Pembrolizumab | Carboplatin and pemetrexed | 2.96 | 1.69 | 1.58 | 1.60 | 0.43 | 0.25 |
5 | Pembrolizumab | Carboplatin and pemetrexed | 3.67 | 2.19 | 1.93 | 1.58 | 1.08 | 0.64 |
6 | Pembrolizumab | – | 1.67 | 1.25 | 1.67 | 1.66 | 0.37 | 0.28 |
7 | Pembrolizumab | – | 2.36 | 2.17 | 1.51 | 1.94 | 0.40 | 0.36 |
8 | Pembrolizumab | – | 3.08 | 1.88 | 1.43 | 1.44 | 0.76 | 0.47 |
9 | Pembrolizumab | Carboplatin and pemetrexed | 2.96 | 1.87 | 1.71 | 1.81 | 0.84 | 0.53 |
10 | Pembrolizumab | Carboplatin and pemetrexed | 3.80 | 2.27 | 1.71 | 1.62 | 1.39 | 0.83 |